Table 1

Baseline data

Group 1 Group 2 Group 3 ANOVA analysis between groups
First year treatmentEOGHGH&EO
Subsequent treatmentGH&EOGH1-150 GH&EO
Number132223
Age (y)9.1 (6.0 to 13.7)9.0 (5.2 to 15.4)9.1 (5.0 to 14.7)NS
Bone age (y)7.9 (3.0 to 13.7)8.0 (3.3 to 13.5)8.1 (3.0 to 12.9)NS
Height (cm)114.0 (94.6 to 140.0)113.2 (93.2 to 135.1)114.9 (93.6 to 139.2)
HSDS for CA−0.1 (−1.5 to +1.8 )−0.3 (−2.1 to +1.2 )0.1 (−2.2 to +1.8 )NS
HSDS for BA1.0 (−0.6 to +2.4 )0.6 (−0.8 to +3.3 )0.8 (−1.6 to +2.7)NS
GH peak (mIU/l) 27.8 (9.5 to 44.0)27.0 (7.9 to 81.0)22.3 (2.8 to 60.0)NS
Mid parental HSDS−0.3 (1.1)−0.2 (0.8)0.7 (1.1)NS
  • Results expressed as mean (range) or (SD).

  • 1-150 Oestrogen introduced after age 12 years.

  • EO, ethinyloestradiol; GH, growth hormone; GH&EO, combined treatment; CA, chronological age; BA, bone age; HSDS, height standard deviation score; NS, not significant.